molecules of
the month

Scientific highlights from recently published drug discovery articles

molecules of the year

Some of the most interesting small molecule drug discovery articles from the last year

about the membership

  • Stay up-to-date with drug discovery highlights for experienced drug hunters
  • Save valuable time with concise, to-the-point summaries of key information
  • Support new content and your industry community with a professional membership

ask your company about a Drug Hunter membership

Member Benefits

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Support new content and build your industry community

Most Recent

ask your company about a Drug Hunter membership

Member Benefits

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Support new content and build your industry community

Coming Up

Careers

molecule of the day

BMS986278 – October

oral LPA1 GPCR receptor antagonist

Ph. II candidate for IPF (60 mg BID)

from addressing tox. of prior candidate

Journal of Medicinal Chemistry

Bristol Myers Squibb, Princeton, NJ

Our Sponsors

Kim Huard

Metabolic Diseases and Novel Targets Drug Discovery

Joachim Rudolph

Oncology Drug Discovery and New Modalities

Callie Bryan

Immunology & Kinase Drug Discovery

View All

Testimonials

  • “Drug Hunter has a great overview of what is happening in our field, saves time on scouring through news feeds, literature and irrelevant stuff that comes up. It is a tool specifically for people like me to weed out the noise. Big time saver.”

    Cyril Bucher

    Drug Discovery Scientist, Denali Therapeutics / Publicly Listed Biotech

  • “I look forward to reading the summaries that come out every month. It helps me keep up to date on what’s going on in the industry.”

    Hilary Beck

    Senior Director, Head of Medicinal Chemistry, Eikon Therapeutics / VC-Backed Biotech

  • “When I need to find information, I know that I can find it on Drug Hunter. This is what was always missing in our field. I’ve been designing drugs for years and the most frustrating part is learning on your own. You may need to go through hundreds of articles to find the information you need. Drug Hunter cuts down on a lot of this!”

    Berenger Biannic

    Associate Director, Drug Discovery, Essa Pharma / Publicly Listed Biotech

  • “Drug Hunter helps keep me up to date with the scientific literature and saves me so much valuable time. Please continue the excellent work!”

    Vincent Guerlavais

    Senior Director of Medicinal Chemistry, Protagonist Therapeutics / Publicly Listed Biotech

  • Testimonial image

    “The thing I like most about it is the concise, to-the-point presentation of the relevant information in an easily digestible format, that is readily accessible to all, from experienced drug hunters to scientists who are just starting their careers. The time-savings achieved by using Drug Hunter are another major selling point. Keep up the good work, folks!”

    David Barrett

    Executive Director, Science and Strategy Advisor, Astellas Pharma

  • Testimonial image

    “I like Drug Hunter! I realize that the team puts so much time and effort into this work and it is not easy work. It is a key opinion leader in the industry. I want Drug Hunter to go on forever. It’s really good!”

    Mark Baik

    Founder and CEO, Arum Therapeutics / Privately Held Biotech

  • Testimonial image

    “Drug Hunter is really good at summarizing all of the key information. It really helps me understand and digest things!”

    Yuebiao Zhou

    Senior Scientist, Drug Discovery, Genentech

  • Testimonial image

    “The cheat sheets that are published are great. Having a centralized resource of those is super helpful. When I recently onboarded a new team member, I taught her about Topliss trees using Drug Hunter. I am way more on top of the med. chem literature because of Drug Hunter!”

    Benjamin Horning

    Senior Scientist, Medicinal Chemistry, Vividion Therapeutics

  • Testimonial image

    “I don’t know of anything similar to this. It’s great that I can visit the site and get a pointer to recent important papers in the field. With the article annotations, I also get a perspective I may not get just by reading papers myself.”

    Matthew Robinson

    Computational Chemist, PostEra

  • “I know I can find new information, targets, and compounds on Drug Hunter each month, which has been really helpful. It’s a good website to see the latest news in drug discovery!”

    TJ Bing

    Senior Group Leader, Pharmaron

  • “Drug Hunters highly informed, relevant science, category-leading approach is time saving, cost saving and importantly a consistent source of inspiration for new Product Development programs. More like this please Drug Hunter!”

    Trevor Brett

    Director of Business Development, Pharmalex

  • Testimonial image

    “I like that Drug Hunter shows condensed information about what is at the forefront of medicinal chemistry at the moment. The molecules are great, I would otherwise have to sift through a lot of articles to find these drugs. I am very satisfied with Drug Hunter.”

    Grant Shibuya

    Medicinal Chemist, RAPT Therapeutics / Publicly Listed Biotech

JOIN SUBSCRIBERS from

  • Johnson & Johnson
  • Roche
  • Pfizer
  • Novartis
  • Bayer
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • AbbVie
  • Eli Lilly
  • Boehringer Ingelheim
  • Amgen
  • Bristol-Myers Squibb
  • Gilead
  • AstraZeneca
  • Teva
  • Novo Nordisk
  • Merck KGaA
  • Takeda
  • Celgene (BMS)
  • Biogen |Astellas
  • Daiichi Sankyo
  • Regeneron
  • UCB
  • Eisai
  • Servier
  • Kyowa Kirin
  • Shionogi
  • Vertex
  • Lundbeck
  • Taisho
  • Ono
  • Seagen
  • Incyte
  • LEO Pharma
  • Janssen
  • Galapagos
  • Idorsia
  • Astex
  • Arvinas
  • Kymera
  • Relay
  • Schrodinger
  • Mirati
  • Revolution
  • Nimbus
  • Plexxikon
  • Forma
  • Arcus
  • RA Capital
  • ARCH Venture Partners
  • MPM Capital
  • Orbimed
  • The Column Group
  • 5AM Ventures
  • Versant Ventures
  • Deerfield
  • Goldman Sachs
  • Citi
  • Piper Sandler
  • Softbank
  • …and hundreds of others

become a member

Help us create more content focused on what’s relevant to professional drug hunters like you by asking your company about a Drug Hunter membership.